+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy



Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy



Current Pharmaceutical Design 14(10): 962-968



Diabetic retinopathy is a common and potentially devastating microvascular complication in diabetes and is a leading cause of acquired blindness among the people of occupational age. However, current therapeutic options for the treatment of sight-threatening proliferative diabetic retinopathy such as photocoagulation and vitrectomy are limited by considerable side effects and far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target diabetic retinopathy is actually desired for most of the patients with diabetes. Chronic hyperglycemia is a major initiator of diabetic retinopathy. However, recent clinical study has substantiated the concept of 'hyperglycemic memory' in the pathogenesis of diabetic retinopathy. Indeed, the Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) Research, has revealed that the reduction in the risk of progressive retinopathy resulting from intensive therapy in patients with type 1 diabetes persisted for at least several years after the DCCT trial, despite increasing hyperglycemia. These findings suggest a long-term beneficial influence of early metabolic control on clinical outcomes in type 1 diabetic patients. Among various biochemical pathways implicated in the pathogenesis of diabetic retinopathy, the process of formation and accumulation of advanced glycation end products (AGEs) and their mode of action are most compatible with the theory 'hyperglycemic memory'. Further, there is a growing body of evidence that AGEs-RAGE (receptor for AGEs) interaction-mediated oxidative stress generation plays an important role in diabetic retinopathy. This article summarizes the role of AGEs and oxidative stress in the development and progression of diabetic retinopathy and the therapeutic interventions that could prevent this devastating disorder. We also discuss here the pathological crosstalk between the AGEs-RAGE and the renin-angiotensin system in diabetic retinopathy and a potential clinical utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma-modulating activity.

(PDF emailed within 1 workday: $29.90)

Accession: 055600551

Download citation: RISBibTeXText

PMID: 18473846


Related references

Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Current Pharmaceutical Biotechnology 12(3): 362-368, 2011

Molecular mechanism of diabetic retinopathy: role of advanced glycation end products(AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy. Nippon Ganka Gakkai Zasshi 109(6): 338-345, 2005

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta 1820(5): 663-671, 2012

Advanced glycation end-products induce oxidative stress through the Sirt1/Nrf2 axis by interacting with the receptor of AGEs under diabetic conditions. Journal of Cellular Biochemistry 2018, 2018

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Current Drug Discovery Technologies 3(1): 83-88, 2006

Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arteriosclerosis, Thrombosis, and Vascular Biology 28(8): 1432-1438, 2008

Possible role of HMG CoA reductase inhibitor on the oxidative stress induced by advanced glycation endproducts(AGEs) in vascular smooth muscle cell(VSMC) of diabetic vasculopathy. 2007

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proceedings of the National Academy of Sciences of the United States of America 91(16): 7742-7746, 1994

Role of advanced glycation end products and activation of PKC in diabetic retinopathy. Nihon Rinsho. Japanese Journal of Clinical Medicine 63 Suppl 6: 188-193, 2005

Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxidative Medicine and Cellular Longevity 3(2): 101-108, 2010

New metabolic marker: Advanced glycation end products (AGEs) and receptor for advanced glycation end products (RAGE) system may play a role in the pathogenesis of recurrent pregnancy losses. Journal of Reproductive Immunology 106: 10-11, 2014

Curcumin inhibits advanced glycation end-products AGEs-induced gene expression of receptor for AGEs RAGE in hepatic stellate cells in vitro by elevating PPAR? activity and attenuating oxidative stress. 2012

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. International Journal of Clinical Pharmacology Research 23(4): 129-134, 2004

Cell signaling and receptors in toxicity of advanced glycation end products (AGEs): α-dicarbonyls, radicals, oxidative stress and antioxidants. Journal of Receptor and Signal Transduction Research 31(5): 332-339, 2012